Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269342 | 1.00 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19TDP1NOS3 | |
| SCHEMBL34468141 | 1.00 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19TDP1NOS3 | |
| SCHEMBL6585508 | 0.95 | — | — | |
| SCHEMBL7075565 | 0.95 | TDP1 (0.41) | CYP2C9TSHRCYP2C19TDP1NOS3 | |
| SCHEMBL2368 | 0.95 | — | — | |
| SCHEMBL3001521 | 0.91 | ACHE (0.42) | CYP2C9TSHRCYP2C19TDP1ACHE | |
| SCHEMBL1269311 | 0.91 | EPHX1 (0.40) | CYP2C9TSHRCYP2C19TDP1NOS3 | |
| Hydrochloric Acid SCHEMBL1937438 | 0.90 | — | — | |
| Ammonia Solution, Strong SCHEMBL3799540 | 0.90 | — | — | |
| Water SCHEMBL17309998 | 0.90 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19TDP1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291684-B2 | Method embodiments for partial hydrogenation of carbocyclic compounds to produce jet fuel blendstock | BATTELLE MEMORIAL INSTITUTE (US) | 2025-05-06 | — | — | US | claimed |
| US-20230193148-A1 | METHOD EMBODIMENTS FOR PARTIAL HYDROGENATION OF CARBOCYCLIC COMPOUNDS TO PRODUCE JET FUEL BLENDSTOCK | BATTELLE MEMORIAL INSTITUTE (US) | 2023-06-22 | — | — | US | claimed |
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| CN-104203993-B | Process for producing olefin polymer | 三井化学株式会社 | 2016-06-15 | — | — | CN | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-05 | — | — | US | disclosed |
| US-12503662-B1 | Cyclooctane containing seal swelling compositions and methods for use of same | CleanJoule, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12291684-B2 | Method embodiments for partial hydrogenation of carbocyclic compounds to produce jet fuel blendstock | BATTELLE MEMORIAL INSTITUTE (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116528811-A | Dry cleaning shampoo composition | 弗门尼舍有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116391022-A | Improved freshness imparting compositions | 弗门尼舍有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-1044972-A1 | 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2000-10-18 | — | — | EP | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-4739120-A | RHODIUM CATALYST, BASIC SOLUTION OR IMMISCIBLE ORGANIC SOLVENT AND WATER | THE DOW CHEMICAL COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | ERG28, DIMT1, MSMO1 | CYP2C9 1594/4885TSHR 3857/4885CYP2C19 2894/4885 |
| US-12503662-B1 | Cyclooctane containing seal swelling compositions and methods for use of same | AQP1, GJA1, DSC1 | CYP2C9 2835/4885TSHR 4878/4885CYP2C19 3722/4885 |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | CPT1A, CPT2, CNR2 | CYP2C9 572/4885TSHR 3620/4885CYP2C19 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.